MICARDIS
LOE ApproachingNDAORALTABLET
Approved
Nov 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
MICARDIS by Boehringer Ingelheim is properties: a thiazide diuretic, hydrochlorothiazide, and an angiotensin ii receptor blocker (arb), telmisartan. Approved for hypertension, to lower blood pressure, alone and 1 more indications. First approved in 1998.
Drug data last refreshed 13h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MICARDIS (telmisartan) is an oral angiotensin II receptor blocker (ARB) indicated for the treatment of hypertension. It works by blocking the angiotensin II receptor, causing vasodilation and reducing blood pressure in patients with essential hypertension.
$2MPart D
LOE ApproachingDeclining
Mature product approaching loss of exclusivity with minimal Part D spending; limited team expansion expected as brand transitions to generic competition.
Mechanism of Action
properties: a thiazide diuretic, hydrochlorothiazide, and an angiotensin II receptor blocker (ARB), telmisartan. Telmisartan Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the…
Indications (4)
Worked on MICARDIS at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.